Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
Takeda Pharmaceutical said on March 4 that it has filed a new drug application in Japan for oveporexton, an oral orexin receptor 2 (OX2R) selective agonist, for the treatment of narcolepsy type 1 (NT1). Designed to address the orexin deficiency…
To read the full story
Related Article
- Takeda’s Orzeyful Inches Closer to Japan Approval as 1st NT1 Drug
August 4, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- Takeda’s OX2R Agonist Makes Mark in PIII NT1 Trials, US Filing Planned in FY2025
July 15, 2025
- TAK-861 Hits Main Goal in PIIb Trial, PIII Set to Begin in 1H FY2024: Takeda
June 6, 2024
BUSINESS
- Medipal Names Imagawa as New CEO in 1st Leadership Change in 14 Years
September 9, 2026
- Kyowa Kirin’s nAMD Med Misses Mark in Global PII Study
September 9, 2026
- Belite Bio Files Stargardt Drug Tinlarebant in Japan
September 9, 2026
- AstraZeneca, Kyushu Electric Power Unit Pilot EV Charging Service
September 9, 2026
- Jardiance Takes Top Spot in Four Promotion Channels in July: Intage
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…